Next Article in Journal
ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients
Next Article in Special Issue
Beyond the Warburg Effect: Oxidative and Glycolytic Phenotypes Coexist within the Metabolic Heterogeneity of Glioblastoma
Previous Article in Journal
The Importance of Stromal Endometriosis in Thoracic Endometriosis
Previous Article in Special Issue
Nanotherapeutic Modulation of Human Neural Cells and Glioblastoma in Organoids and Monocultures
Open AccessReview

Hippo Signaling Pathway in Gliomas

Inserm U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, F-86073 Poitiers, France
Université de Poitiers, F-86073 Poitiers, France
CHU de Poitiers, Laboratoire de Cancérologie Biologique, F-86022 Poitiers, France
Author to whom correspondence should be addressed.
Cells 2021, 10(1), 184;
Received: 16 December 2020 / Revised: 12 January 2021 / Accepted: 15 January 2021 / Published: 18 January 2021
(This article belongs to the Special Issue Molecular and Cellular Mechanisms of Cancers: Glioblastoma)
The Hippo signaling pathway is a highly conserved pathway involved in tissue development and regeneration that controls organ size through the regulation of cell proliferation and apoptosis. The core Hippo pathway is composed of a block of kinases, MST1/2 (Mammalian STE20-like protein kinase 1/2) and LATS1/2 (Large tumor suppressor 1/2), which inhibits nuclear translocation of YAP/TAZ (Yes-Associated Protein 1/Transcriptional co-activator with PDZ-binding motif) and its downstream association with the TEAD (TEA domain) family of transcription factors. This pathway was recently shown to be involved in tumorigenesis and metastasis in several cancers such as lung, breast, or colorectal cancers but is still poorly investigated in brain tumors. Gliomas are the most common and the most lethal primary brain tumors representing about 80% of malignant central nervous system neoplasms. Despite intensive clinical protocol, the prognosis for patients remains very poor due to systematic relapse and treatment failure. Growing evidence demonstrating the role of Hippo signaling in cancer biology and the lack of efficient treatments for malignant gliomas support the idea that this pathway could represent a potential target paving the way for alternative therapeutics. Based on recent advances in the Hippo pathway deciphering, the main goal of this review is to highlight the role of this pathway in gliomas by a state-of-the-art synthesis. View Full-Text
Keywords: gliomas; glioblastomas; hippo signaling pathway; MST1/2; LATS1/2; YAP/TAZ; TEADs gliomas; glioblastomas; hippo signaling pathway; MST1/2; LATS1/2; YAP/TAZ; TEADs
Show Figures

Figure 1

MDPI and ACS Style

Masliantsev, K.; Karayan-Tapon, L.; Guichet, P.-O. Hippo Signaling Pathway in Gliomas. Cells 2021, 10, 184.

AMA Style

Masliantsev K, Karayan-Tapon L, Guichet P-O. Hippo Signaling Pathway in Gliomas. Cells. 2021; 10(1):184.

Chicago/Turabian Style

Masliantsev, Konstantin; Karayan-Tapon, Lucie; Guichet, Pierre-Olivier. 2021. "Hippo Signaling Pathway in Gliomas" Cells 10, no. 1: 184.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop